BioTech

CEO Of T-Mobile US Inc (NASDAQ:TMUS) Has Eight Predictions For 2017

CEO Of T-Mobile US Inc (NASDAQ:TMUS) Has Eight Predictions For 2017

January 9, 2017 at 8:28 am 0 comments

The CEO of T-Mobile Us Inc (NYSE:PCS), John Legere made a few predictions about the coming year, at the CES 2017 meeting, some of which, he directly bashed against his rival’s defense. The event itself took place in Las Vegas. Legere is somewhat of a novelty when it comes toRead More

eBay Inc (NASDAQ:EBAY) Creates Its Own Framework To Combine Kubernetes And Openstack

eBay Inc (NASDAQ:EBAY) Creates Its Own Framework To Combine Kubernetes And Openstack

January 3, 2017 at 3:00 am 0 comments

In a recent attempt to keep its developers merry and bright, eBay Inc (NASDAQ:EBAY) recently announced building its indigenous framework, TessMaster, for integrating Kubernetes and OpenStack. In order to make sure that the company developers remain satiated, this e-commerce giant has focussed on several innovative challenges. TessMaster is eBay’s managementRead More

Mylan NV (NASDAQ:MYL) EpiPen To Be Sold By Mylan At A Big Discount

Mylan NV (NASDAQ:MYL) EpiPen To Be Sold By Mylan At A Big Discount

December 19, 2016 at 7:24 am 0 comments

Mylan NV (NASDAQ:MYL) has offered to sell EpiPen, an anti-allergy device, at a price a price that’s equivalent to a 50% discount. The pharmaceutical firm has said that a two-pack generic version of EpiPen will be priced at $300. This will be half the price of its similarly-named original version.Read More

Bristol-Myers, Eli Lilly and Merck Collaborating on Cancer Drug Studies

January 13, 2015 at 10:22 am 0 comments

Bristol-Myers Squibb Co (NYSE:BMY) and Eli Lilly and Co (NYSE:LLY) have agreed to a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo in combination with Lilly’s galunisertib as a potential treatment option for patients with advanced glioblastoma, hepatocellular carcinoma and non-small cell lung cancer. The studyRead More

Ceres Inc (NASDAQ:CERE) Shares up on Positive News

January 9, 2015 at 7:40 am 0 comments

Ceres Inc (NASDAQ:CERE), an agricultural biotechnology company, reported its multi-gene combinations in corn achieved an approximately 25% yield advantage over controls in many of its research-scale field evaluations involving two different hybrids. The company said a second year of field trials in China demonstrated significant yield advantages under normal andRead More

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Jumps on Encouraging Preclinical Data

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Jumps on Encouraging Preclinical Data

January 6, 2015 at 10:49 am 0 comments

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares climbed in Tuesday’s pre-market session, after the biopharmaceutical company published preclinical data for its RX-3117 showing the treatment was effective against gemcitabine-resistant human cancer cells. Rexahn Pharmaceuticals, Inc. (RNN) was up 9.5% at $0.81 in recent pre-market trading, in a 52-week range of $0.55 to $1.85. In theRead More